Considering that the neutralizing effects of anti-IFN-γ autoAbs on the IFN-γ signaling pathway are mediated by targeting STAT1 transactivation and chemokine production, we also revealed significantly lower levels of plasma MCP-1 in RA patients with new-onset HZ compared to those without HZ. This evidence concerns the gene STAT1 and rheumatoid arthritis.